Navigation Links
Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
Date:9/24/2009

www.dendreon.com.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE and requisite receipt of FDA licensure for marketing and the risk that additional capital could be needed in the future for the potential commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
2. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
3. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
4. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
5. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
6. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
7. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
8. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
9. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
10. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
11. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... FREDERICK, Md. , May 23, 2013  BioElectronics ... safe consumer medical devices, comments on the FDA panel ... Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting ... Gaithersburg, MD , USA.  The focus of the ... instructed the panel to focus solely on the application ...
(Date:5/23/2013)... 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... David A. Ramsay as ... Vice President, Corporate Development at Halozyme. ... his established financial management experience and his recent ... our commercial group for the last four years, ...
(Date:5/23/2013)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), ... present a company overview at the Deutsche Bank 38 th ... 2013 at 8:40 a.m. ET in Boston, MA. ... presentation will be available on the "Investors & Media" section ... will be available on the Isis Web site within 48 ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... with the National Institute of Allergy and ... biodefense,research, under which the NIAID will conduct ... as a treatment for,anthrax and other high-priority ...
... Compound, AHLi-11, Slated for IND Filing By ... ... Quark Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company focused on discovering and,developing novel ... the State University of New York at,Buffalo, Center for Hearing & ...
Cached Medicine Technology:Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 2Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 3Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 4
(Date:5/23/2013)... New York, New York (PRWEB) May 23, 2013 ... dedicated to protecting the rights of victims injured by ... that Senior Litigation Counsel Matthew J. McCauley has been ... entitled In Re: Mirena IUD Products Liability Litigation (Case ... states that Co-Lead and Liaison Counsel are to submit ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 EnvirOasis, ... the contractor and ESCO market is pleased to announce ... Consortium (DLC) Listed LED products. EnvirOasis has been ... fixtures and retrofit kits and has recently brought ... LED (Light Emitting Diode) is energy efficient lighting ...
(Date:5/23/2013)... News) -- The sensation of itching is hardwired into ... a small molecule released in the spinal cord, according ... say this molecule, known as natriuretic polypeptide b (Nppb), ... system. Ultimately, this signal is experienced as an itch. ... similar, the researchers concluded that a similar process probably ...
(Date:5/23/2013)... May 23 (HealthDay News) -- Teen birth rates in the ... to a new government report. Overall, the rate of ... one half from 1991 to 2011 -- from about 62 ... 1,000. From 2007 to 2011, the most recent time ... 31. During that time, rates fell at least 30 ...
(Date:5/23/2013)... (HealthDay News) -- A shortage of a critical tuberculosis ... the United States to contain the spread of the ... drug, isoniazid (INH), was first used in 1951 and ... core of any first-line treatment for tuberculosis (TB). Patients ... according to the U.S. Centers for Disease Control and ...
Breaking Medicine News(10 mins):Health News:U.S. District Court Appoints Parker Waichman LLP’s Matthew J. McCauley to Leadership Role in Mirena IUD Litigation 2Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2
... ANN ARBOR, Mich. Head and neck cancer patients ... more symptoms of chronic pain and complaints of dry mouth ... the University of Michigan Comprehensive Cancer Center. Because these ... that reducing these factors in head and neck cancer patients ...
... touchscreens, housed in computer kiosks at clinics and ... School of Medicine and clinicians at local health ... diverse language, literacy and computer skills. The ... and collect patient data. Each piece of text ...
... Gordon HealthDay Reporter , FRIDAY, July 9 (HealthDay ... and well-being of America,s children, a group of 22 federal ... pregnancies in particular, but bad news in other areas, like ... is a status update on how our nation,s children are ...
... Researchers at Brown University have found that the length of ... doubled during the last 10 years. The study, which will ... the American Geriatrics Society , evaluated hospice use in U.S. ... treatment time has increased from 46 to 93 days. The ...
... ... used cosmetic lasers and other used aesthetic equipment by more than 30% to meet the ... to their patients. , ... Ft. Lauderdale, FL (PRWEB) July 9, 2010 -- The Laser Warehouse has increased its ...
... ... in 2002, the association has accredited certification bodies that represent more than ... Medical Sales Representatives) RMSR Certification has been recently cited with the U. ... sole approved accreditor of certification bodies for entry level Medical Device & ...
Cached Medicine News:Health News:Pain, dry mouth may play role in sleep quality of head and neck cancer patients 2Health News:Pain, dry mouth may play role in sleep quality of head and neck cancer patients 3Health News:Talking touchscreens aid patients 2Health News:U.S. Report on Kids' Health Brings Mixed Results 2Health News:U.S. Report on Kids' Health Brings Mixed Results 3Health News:Study: Medicare policy may account for growing length of hospice stays in nursing homes 2Health News:The Laser Warehouse Increases its Inventory of Used Cosmetic Lasers to Meet Growing Demand 2Health News:The Laser Warehouse Increases its Inventory of Used Cosmetic Lasers to Meet Growing Demand 3Health News:RMSR Certification Gains Medical Device & Equipment Industry Acceptance for Medical Sales Reps 2Health News:RMSR Certification Gains Medical Device & Equipment Industry Acceptance for Medical Sales Reps 3